AR066238A1 - Metodos de produccion de proteinas mediante la utilizacion de compuestos anti-senescencia - Google Patents
Metodos de produccion de proteinas mediante la utilizacion de compuestos anti-senescenciaInfo
- Publication number
- AR066238A1 AR066238A1 ARP080101677A ARP080101677A AR066238A1 AR 066238 A1 AR066238 A1 AR 066238A1 AR P080101677 A ARP080101677 A AR P080101677A AR P080101677 A ARP080101677 A AR P080101677A AR 066238 A1 AR066238 A1 AR 066238A1
- Authority
- AR
- Argentina
- Prior art keywords
- methods
- aging compound
- protein production
- cells
- culture medium
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 230000014616 translation Effects 0.000 title 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 abstract 3
- 230000003712 anti-aging effect Effects 0.000 abstract 3
- 102000003298 tumor necrosis factor receptor Human genes 0.000 abstract 3
- 238000004113 cell culture Methods 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 abstract 1
- 108010087806 Carnosine Proteins 0.000 abstract 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 abstract 1
- 229940044199 carnosine Drugs 0.000 abstract 1
- 239000006143 cell culture medium Substances 0.000 abstract 1
- 239000001963 growth medium Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000035899 viability Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
- C12N2500/33—Amino acids other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Métodos para producir una proteína, tal como la proteína de fusion TNFR (receptor del factor de necrosis tumoral), en un cultivo celular que comprende un compuesto anti-envejecimiento, tal como el antioxidante carnosina. Las células que sedesarrollan en un medio de cultivo de células que comprende un compuesto anti-envejecimiento exhiben un aumento de la viabilidad y de la productividad. Además, los cultivos celulares desarrollados en presencia de un compuesto anti-envejecimientoexhiben una disminucion en los niveles de agregados de alto peso molecular en el medio de cultivo e células. También una proteína de fusion TNFR producida por dicho método.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91338207P | 2007-04-23 | 2007-04-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066238A1 true AR066238A1 (es) | 2009-08-05 |
Family
ID=39493848
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101677A AR066238A1 (es) | 2007-04-23 | 2008-04-22 | Metodos de produccion de proteinas mediante la utilizacion de compuestos anti-senescencia |
| ARP080101678A AR066239A1 (es) | 2007-04-23 | 2008-04-22 | Metodo para la produccion de proteinas mediante celulas cultivadas |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101678A AR066239A1 (es) | 2007-04-23 | 2008-04-22 | Metodo para la produccion de proteinas mediante celulas cultivadas |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US12054762B2 (es) |
| EP (2) | EP2139987B9 (es) |
| JP (3) | JP5557736B2 (es) |
| KR (3) | KR101560421B1 (es) |
| CN (3) | CN101679943A (es) |
| AR (2) | AR066238A1 (es) |
| AU (2) | AU2008242632B2 (es) |
| BR (2) | BRPI0810511A2 (es) |
| CA (2) | CA2685552C (es) |
| CL (2) | CL2008001159A1 (es) |
| CO (2) | CO6241165A2 (es) |
| DK (2) | DK2139987T5 (es) |
| ES (2) | ES2646090T3 (es) |
| HK (1) | HK1216261A1 (es) |
| HU (1) | HUE034776T2 (es) |
| IL (2) | IL201720A (es) |
| MX (2) | MX2009011363A (es) |
| PA (2) | PA8777701A1 (es) |
| PE (2) | PE20090731A1 (es) |
| PL (2) | PL2139987T3 (es) |
| PT (2) | PT2139986T (es) |
| RU (2) | RU2478702C2 (es) |
| SI (2) | SI2139987T1 (es) |
| TW (2) | TW200902708A (es) |
| WO (2) | WO2008131375A1 (es) |
| ZA (1) | ZA200907426B (es) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
| RU2518289C2 (ru) | 2006-09-13 | 2014-06-10 | Эббви Инк, | Способ получения антитела или его фрагмента с подпиткой (варианты) |
| KR20090127326A (ko) | 2007-03-02 | 2009-12-10 | 와이어쓰 | 폴리펩티드의 생산을 위한 세포 배양물 중에서 구리 및 글루타메이트의 용도 |
| WO2009023562A2 (en) * | 2007-08-09 | 2009-02-19 | Wyeth | Use of perfusion to enhance production of fed-batch cell culture in bioreactors |
| US8937046B2 (en) | 2008-09-22 | 2015-01-20 | The Regents Of The University Of Colorado, A Body Corporate | Modulating the alternative complement pathway |
| TW201024318A (en) * | 2008-10-20 | 2010-07-01 | Abbott Lab | Isolation and purification of antibodies using protein A affinity chromatography |
| NZ592097A (en) | 2008-10-20 | 2013-01-25 | Abbott Lab | Viral inactivation during purification of il-12 and il-18 antibodies |
| WO2011068993A1 (en) * | 2009-12-02 | 2011-06-09 | Acceleron Pharma Inc. | Compositions and methods for increasing serum half-life of fc fusion proteins. |
| EP3862423A1 (en) | 2010-04-26 | 2021-08-11 | Novartis AG | Improved cell cultivation process |
| JP6001456B2 (ja) * | 2010-12-28 | 2016-10-05 | 中外製薬株式会社 | 動物細胞の培養方法 |
| US9062106B2 (en) | 2011-04-27 | 2015-06-23 | Abbvie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| EP2718328A4 (en) | 2011-06-08 | 2014-12-24 | Acceleron Pharma Inc | COMPOSITIONS AND METHODS FOR INCREASING THE HALF TIME OF SERUM |
| US9334319B2 (en) | 2012-04-20 | 2016-05-10 | Abbvie Inc. | Low acidic species compositions |
| US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| US9206390B2 (en) | 2012-09-02 | 2015-12-08 | Abbvie, Inc. | Methods to control protein heterogeneity |
| SG11201507230PA (en) | 2013-03-12 | 2015-10-29 | Abbvie Inc | Human antibodies that bind human tnf-alpha and methods of preparing the same |
| WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| US8921526B2 (en) | 2013-03-14 | 2014-12-30 | Abbvie, Inc. | Mutated anti-TNFα antibodies and methods of their use |
| KR20210037745A (ko) | 2013-03-15 | 2021-04-06 | 제넨테크, 인크. | 항산화제를 함유하는 세포 배양 조성물 및 폴리펩티드 생산 방법 |
| SG11201507875RA (en) * | 2013-03-26 | 2015-10-29 | Coherus Biosciences Inc | Protein production method |
| TW201446961A (zh) | 2013-05-06 | 2014-12-16 | Abbvie Inc | 用於細胞培養之組合物及其使用方法 |
| WO2015051293A2 (en) | 2013-10-04 | 2015-04-09 | Abbvie, Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| USD759075S1 (en) * | 2014-04-11 | 2016-06-14 | Nutonian, Inc. | Display screen with graphical user interface |
| USD759076S1 (en) * | 2014-04-18 | 2016-06-14 | Nutonian, Inc. | Display screen with graphical user interface |
| TW202204596A (zh) | 2014-06-06 | 2022-02-01 | 美商健臻公司 | 灌注培養方法及其用途 |
| EP3207132B1 (en) * | 2014-10-15 | 2019-07-31 | Alexion Pharmaceuticals, Inc. | Methods of shifting an isoelectric profile of a protein product and uses thereof |
| AR104050A1 (es) | 2015-03-26 | 2017-06-21 | Chugai Pharmaceutical Co Ltd | Proceso de producción con iones de cobre controlados |
| TWI797060B (zh) | 2015-08-04 | 2023-04-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| WO2017065559A1 (ko) * | 2015-10-15 | 2017-04-20 | (주)알테오젠 | Igg fc 도메인을 가지는 융합 단백질의 생산방법 |
| KR101936049B1 (ko) | 2015-10-15 | 2019-01-08 | (주)알테오젠 | IgG Fc 도메인을 가지는 융합 단백질의 생산방법 |
| CN107460221B (zh) * | 2016-06-02 | 2021-01-15 | 正大天晴药业集团股份有限公司 | 一种降低抗pd-l1抗体中蛋白聚合物的细胞培养方法 |
| EP3529350A1 (en) | 2016-10-19 | 2019-08-28 | H. Hoffnabb-La Roche Ag | Method for producing an immunoconjugate |
| JP7252896B2 (ja) * | 2017-02-17 | 2023-04-05 | ロンザ リミテッド | 生物学的産物バリアントを産生する方法 |
| US20190112569A1 (en) * | 2017-10-16 | 2019-04-18 | Regeneron Pharmaceuticals, Inc. | In Situ Raman Spectroscopy Systems and Methods for Controlling Process Variables in Cell Cultures |
| CN119161488A (zh) | 2017-11-01 | 2024-12-20 | 中外制药株式会社 | 具有降低的生物活性的抗体变体和同种型 |
| JP7707062B2 (ja) * | 2018-11-02 | 2025-07-14 | ウーシー バイオロジクス アイルランド リミテッド | 連続的採取を行い細胞流出を行わない強化灌流による細胞培養法 |
| JP7570341B2 (ja) * | 2019-03-04 | 2024-10-21 | アムジエン・インコーポレーテツド | 高分子量種のインビボでの可逆性 |
| BR112022013255A2 (pt) | 2020-01-09 | 2022-09-06 | Mersana Therapeutics Inc | Conjugados anticorpo-fármaco específicos de sítio com ligantes contendo peptídeo |
| JP2022184798A (ja) * | 2021-06-01 | 2022-12-13 | ファイザー・インク | ｓＦＧＦＲ３ポリペプチドを生産するための細胞培養方法 |
| KR102682066B1 (ko) * | 2021-10-12 | 2024-07-05 | 프레스티지바이오로직스 주식회사 | 항체 집단의 제조 방법 |
| EP4640838A1 (en) * | 2022-12-23 | 2025-10-29 | Cell Exosome Therapeutics Inc. | Utilization of mesenchymal stem cells or culture supernatant thereof |
| CN120752329A (zh) * | 2023-02-03 | 2025-10-03 | 安进公司 | 细胞培养方法 |
| CN118166053B (zh) * | 2024-03-15 | 2025-02-07 | 通化安睿特生物制药股份有限公司 | 一种制备低o-糖基化水平的重组人白蛋白的方法 |
| CN118006716B (zh) * | 2024-03-15 | 2024-09-10 | 通化安睿特生物制药股份有限公司 | 制备高表达且低o-糖基化水平的重组人白蛋白的方法 |
| TWI891362B (zh) * | 2024-05-10 | 2025-07-21 | 國立臺灣大學 | 鴨蛋白水解物及其製備方法及增強肌肉耐力與抗疲勞用途 |
| WO2025248500A1 (en) | 2024-05-31 | 2025-12-04 | Janssen Biotech, Inc. | Antibody drug conjugates that target enpp3 |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| CA1340288C (en) | 1988-09-02 | 1998-12-29 | Robert Charles Ladner | Generation and selection of novel binding proteins |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| JPH0396383A (ja) | 1989-09-08 | 1991-04-22 | Riso Kagaku Corp | 画像形成装置 |
| DE59010908D1 (de) | 1989-09-12 | 2000-08-10 | Hoffmann La Roche | TNF-bindende Proteine |
| GB8927546D0 (en) | 1989-12-06 | 1990-02-07 | Ciba Geigy | Process for the production of biologically active tgf-beta |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5610033A (en) | 1990-04-25 | 1997-03-11 | Novo Nordisk A/S | Method of producing proteins with FVIII activity and/or FVIII derivatives |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9021679D0 (en) | 1990-10-05 | 1990-11-21 | Gorman Scott David | Antibody preparation |
| GB9022545D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
| WO1992009298A1 (en) * | 1990-11-23 | 1992-06-11 | Peptide Technology Ltd. | The delay, prevention and/or reversal of cell senescence |
| ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
| WO1992015677A1 (en) | 1991-03-01 | 1992-09-17 | Protein Engineering Corporation | Process for the development of binding mini-proteins |
| ATE269401T1 (de) | 1991-04-10 | 2004-07-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| DE122004000008I1 (de) * | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| US6136310A (en) | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
| EP1589107B1 (en) | 1992-08-21 | 2009-12-23 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| US5399677A (en) | 1993-12-07 | 1995-03-21 | Genetics Institute, Inc. | Mutants of bone morphogenetic proteins |
| GB2285446B (en) | 1994-01-03 | 1999-07-28 | Genentech Inc | Thrombopoietin |
| US5516964A (en) | 1994-01-21 | 1996-05-14 | Sun Company, Inc. (R&M) | Hydrocarbon isomerization using solid superacid catalysts comprising platinum metal |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5721121A (en) * | 1995-06-06 | 1998-02-24 | Genentech, Inc. | Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein |
| US5705364A (en) * | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
| US5830761A (en) * | 1995-06-07 | 1998-11-03 | Genetics Institute, Inc. | Medium and methods for culturing mammalian cho cells |
| WO1997008320A1 (en) * | 1995-08-18 | 1997-03-06 | Morphosys Gesellschaft Für Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
| JP4306813B2 (ja) | 1995-09-19 | 2009-08-05 | アスビオファーマ株式会社 | 動物細胞の新規培養方法 |
| US5710023A (en) | 1996-03-01 | 1998-01-20 | Genetics Institute, Inc. | IL-13 cytokine receptor chain |
| US6146847A (en) * | 1996-11-01 | 2000-11-14 | Genespan Corporation | Stabilized transient gene expression |
| JP4215172B2 (ja) * | 1996-12-03 | 2009-01-28 | アムジェン フレモント インク． | 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体 |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| WO1999035255A2 (en) | 1998-01-12 | 1999-07-15 | Betagene, Inc. | Compositions and methods for regulated secretion from neuroendocrine cell lines |
| CA2342967A1 (en) | 1998-12-08 | 2000-06-15 | Biovation Limited | Modifying protein immunogenicity |
| TR200504220T2 (tr) * | 1998-12-17 | 2007-04-24 | Biogen Idec Ma Inc. | Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem. |
| US7294481B1 (en) | 1999-01-05 | 2007-11-13 | Immunex Corporation | Method for producing recombinant proteins |
| DE60042114D1 (de) | 1999-04-30 | 2009-06-10 | Craig J Venter Inst Inc | Genomische sequenzen von neisseria und verfahren zu ihrer verwendung |
| JP3090657B1 (ja) | 1999-08-09 | 2000-09-25 | 伸子 蓮山 | ゼオライト製造方法およびゼオライト製造装置 |
| EP1103615A1 (en) | 1999-11-25 | 2001-05-30 | Universite De Geneve | Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors |
| AUPR038200A0 (en) * | 2000-09-26 | 2000-10-19 | Beta Peptide Foundation Pty Ltd, The | Compositions and methods for delaying, preventing, rejuvenating or reversing senescence |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030040095A1 (en) * | 2001-03-16 | 2003-02-27 | Achille Arini | Method for the production of pharmaceutically active recombinant proteins |
| US20040058445A1 (en) | 2001-04-26 | 2004-03-25 | Ledbetter Jeffrey Alan | Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB |
| US6544076B2 (en) | 2001-07-10 | 2003-04-08 | Alan L. Pocrass | Dual function RJ connector |
| EP1448786B1 (en) * | 2001-11-19 | 2010-04-14 | Novo Nordisk A/S | Process for preparing insulin compounds |
| CA2417689C (en) | 2002-03-05 | 2006-05-09 | F. Hoffmann-La Roche Ag | Improved methods for growing mammalian cells in vitro |
| US6872549B2 (en) * | 2002-03-27 | 2005-03-29 | Immunex Corporation | Methods for increasing polypeptide production |
| GB0208041D0 (en) | 2002-04-08 | 2002-05-22 | Lonza Biologics Plc | Method of culturing animal cells |
| EP1520008B1 (en) | 2002-07-09 | 2012-09-05 | Baxter International Inc. | Animal protein free media for cultivation of cells |
| PL376381A1 (en) | 2002-07-15 | 2005-12-27 | Immunex Corporation | Methods and media for controlling sialylation of proteins produced by mammalian cells |
| US6924124B1 (en) | 2002-08-23 | 2005-08-02 | Immunex Corporation | Feeding strategies for cell culture |
| US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| AU2003300276B2 (en) | 2002-12-23 | 2010-07-01 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
| EP1620457A2 (en) | 2003-04-25 | 2006-02-01 | Immunex Corporation | Inducers of recombinant protein expression |
| CN1565631A (zh) * | 2003-06-27 | 2005-01-19 | 上海中信国健药业有限公司 | 肿瘤坏死因子受体－免疫球蛋白的融合蛋白用于急性肺损伤药物的用途 |
| PL1678208T3 (pl) | 2003-10-27 | 2013-09-30 | Wyeth Llc | Usuwanie agregatów o wysokiej masie cząsteczkowej z użyciem chromatografii na hydroksyapatycie |
| WO2005064013A1 (en) | 2003-12-23 | 2005-07-14 | Bart Janssen | The use of carnosine metabolism-associated genes to determine genetic predisposition/susceptibility to diabetic nephropathy |
| ATE464918T1 (de) * | 2004-07-07 | 2010-05-15 | Coloplast As | Herstellung von hydrophilen überzügen mit einer 1,3-dioxolan-verbindung |
| CN103172731A (zh) | 2004-07-15 | 2013-06-26 | 赞科股份有限公司 | 优化的Fc变体 |
| EP1781684A4 (en) | 2004-08-25 | 2008-05-21 | Amprotein Corp | NEW CHIMERE POLYPEPTIDE AND USE THEREOF |
| US7294484B2 (en) * | 2004-08-27 | 2007-11-13 | Wyeth Research Ireland Limited | Production of polypeptides |
| TWI374935B (en) * | 2004-08-27 | 2012-10-21 | Pfizer Ireland Pharmaceuticals | Production of α-abeta |
| TWI364458B (en) * | 2004-08-27 | 2012-05-21 | Wyeth Res Ireland Ltd | Production of tnfr-lg |
| US7426440B2 (en) * | 2004-09-24 | 2008-09-16 | Nutritional Bioscience Ltd. | Repair and protection factor scoring method for bioactive agents |
| US20070102622A1 (en) | 2005-07-01 | 2007-05-10 | Olsen Richard I | Apparatus for multiple camera devices and method of operating same |
| WO2007011595A2 (en) | 2005-07-15 | 2007-01-25 | Neuren Pharmaceuticals Limited | Neural regeneration peptides and antioxidants protect neurons from degeneration |
| DE102005034616B4 (de) * | 2005-07-18 | 2008-07-03 | Elringklinger Ag | Brennstoffzelleneinheit und Brennstoffzellenstapel |
| AR058140A1 (es) * | 2005-10-24 | 2008-01-23 | Wyeth Corp | Metodo de produccion proteica utilizando compuestos anti-senescencia |
| RU2463345C2 (ru) * | 2006-07-13 | 2012-10-10 | Вайет | Получение гликопротеинов |
| KR20090127326A (ko) | 2007-03-02 | 2009-12-10 | 와이어쓰 | 폴리펩티드의 생산을 위한 세포 배양물 중에서 구리 및 글루타메이트의 용도 |
| WO2009023562A2 (en) | 2007-08-09 | 2009-02-19 | Wyeth | Use of perfusion to enhance production of fed-batch cell culture in bioreactors |
| JP7587678B2 (ja) | 2021-09-15 | 2024-11-20 | 香港時代新能源科技有限公司 | 電池セル、電池、電力消費装置、電池セルの製造方法及び設備 |
-
2008
- 2008-04-10 TW TW097112974A patent/TW200902708A/zh unknown
- 2008-04-21 PE PE2008000686A patent/PE20090731A1/es not_active Application Discontinuation
- 2008-04-22 PE PE2008000691A patent/PE20090153A1/es not_active Application Discontinuation
- 2008-04-22 BR BRPI0810511-1A2A patent/BRPI0810511A2/pt not_active Application Discontinuation
- 2008-04-22 KR KR1020097024259A patent/KR101560421B1/ko active Active
- 2008-04-22 BR BRPI0810482-4A2A patent/BRPI0810482A2/pt not_active Application Discontinuation
- 2008-04-22 CN CN200880013275A patent/CN101679943A/zh active Pending
- 2008-04-22 AR ARP080101677A patent/AR066238A1/es unknown
- 2008-04-22 HU HUE08746526A patent/HUE034776T2/en unknown
- 2008-04-22 DK DK08746528.2T patent/DK2139987T5/da active
- 2008-04-22 JP JP2010506424A patent/JP5557736B2/ja active Active
- 2008-04-22 AR ARP080101678A patent/AR066239A1/es unknown
- 2008-04-22 US US12/107,533 patent/US12054762B2/en active Active
- 2008-04-22 PT PT87465266T patent/PT2139986T/pt unknown
- 2008-04-22 PT PT87465282T patent/PT2139987E/pt unknown
- 2008-04-22 KR KR1020097023172A patent/KR101540124B1/ko active Active
- 2008-04-22 EP EP08746528.2A patent/EP2139987B9/en active Active
- 2008-04-22 CN CN200880013317.1A patent/CN101668845B/zh active Active
- 2008-04-22 AU AU2008242632A patent/AU2008242632B2/en active Active
- 2008-04-22 PL PL08746528T patent/PL2139987T3/pl unknown
- 2008-04-22 CN CN201510351048.1A patent/CN105039473A/zh active Pending
- 2008-04-22 KR KR20147030274A patent/KR20140132016A/ko not_active Ceased
- 2008-04-22 MX MX2009011363A patent/MX2009011363A/es active IP Right Grant
- 2008-04-22 EP EP08746526.6A patent/EP2139986B1/en not_active Revoked
- 2008-04-22 CA CA2685552A patent/CA2685552C/en not_active Expired - Fee Related
- 2008-04-22 ES ES08746526.6T patent/ES2646090T3/es active Active
- 2008-04-22 WO PCT/US2008/061125 patent/WO2008131375A1/en not_active Ceased
- 2008-04-22 US US12/107,264 patent/US9988662B2/en active Active
- 2008-04-22 ES ES08746528T patent/ES2424217T3/es active Active
- 2008-04-22 JP JP2010506425A patent/JP2010524504A/ja active Pending
- 2008-04-22 PL PL08746526T patent/PL2139986T3/pl unknown
- 2008-04-22 PA PA20088777701A patent/PA8777701A1/es unknown
- 2008-04-22 RU RU2009139054/10A patent/RU2478702C2/ru active
- 2008-04-22 TW TW097114607A patent/TW200902709A/zh unknown
- 2008-04-22 SI SI200830998T patent/SI2139987T1/sl unknown
- 2008-04-22 DK DK08746526.6T patent/DK2139986T3/en active
- 2008-04-22 WO PCT/US2008/061123 patent/WO2008131374A1/en not_active Ceased
- 2008-04-22 CA CA2684727A patent/CA2684727C/en active Active
- 2008-04-22 SI SI200831866T patent/SI2139986T1/sl unknown
- 2008-04-22 AU AU2008242633A patent/AU2008242633B2/en active Active
- 2008-04-22 CL CL2008001159A patent/CL2008001159A1/es unknown
- 2008-04-22 MX MX2009011362A patent/MX2009011362A/es active IP Right Grant
- 2008-04-22 CL CL2008001156A patent/CL2008001156A1/es unknown
- 2008-04-22 RU RU2009138226/10A patent/RU2009138226A/ru not_active Application Discontinuation
- 2008-04-23 PA PA20088778001A patent/PA8778001A1/es unknown
-
2009
- 2009-10-21 CO CO09117978A patent/CO6241165A2/es not_active Application Discontinuation
- 2009-10-22 IL IL201720A patent/IL201720A/en active IP Right Grant
- 2009-10-22 IL IL201719A patent/IL201719A/en active IP Right Grant
- 2009-10-22 ZA ZA200907426A patent/ZA200907426B/xx unknown
- 2009-10-22 CO CO09118627A patent/CO6241166A2/es not_active Application Discontinuation
-
2014
- 2014-01-31 JP JP2014016511A patent/JP5881755B2/ja active Active
-
2016
- 2016-04-13 HK HK16104245.7A patent/HK1216261A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR066238A1 (es) | Metodos de produccion de proteinas mediante la utilizacion de compuestos anti-senescencia | |
| NI200800111A (es) | Método de producción proteica utilizando compuestos anti-senescencia | |
| ES2560470T3 (es) | Un método para reducir la heterogeneidad de anticuerpos y un proceso de producción de dichos anticuerpos | |
| MX2021009967A (es) | Metodos para producir celulas t autologas utiles para tratar cancer y composiciones de las mismas. | |
| BR112015023036A2 (pt) | método para preparar um produto alcaloide benzilisoquinolina e célula microbiana engenheirada que produz um produto alcaloide benzilisoquinolina | |
| SG10201810830UA (en) | Cell culture compositions and methods for polypeptide production | |
| MX2010000944A (es) | Vectores baculovirales que comprenden secuencias de codificacion repetida con deformaciones diferenciales en codones. | |
| EA201201435A1 (ru) | ГЕТЕРОДИМЕРНЫЕ АНТИТЕЛО-Fc-СОДЕРЖАЩИЕ БЕЛКИ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ | |
| BR112012019023A2 (pt) | método para produzir adenovírus recombinante sorotipo 26 (rad26), e, usoi de um biorreator | |
| CO6680636A2 (es) | Método para producir adamts13 recombinante en cultivo celular | |
| UY31947A (es) | Procedimiento mejorado para la preparacion de 2-trifluorometil-5-(1-substituido)alquilpiridina | |
| TR201900213T4 (tr) | Bir sürekli hücre kültüründe bir polipeptit veya ilişkin virüsün üretim metodu. | |
| EP4324913A3 (en) | Culture media for stem cells | |
| MX382693B (es) | Polipéptidos híbridos y quiméricos del factor viii-fc, y métodos de uso de los mismos. | |
| AR069776A1 (es) | Anticuerpos bivalentes biespecificos | |
| MX360779B (es) | Composiciones de cultivo celular con antioxidantes y métodos para la producción de polipéptidos. | |
| AR095348A1 (es) | Medios de cultivo celular y métodos de producción de anticuerpos | |
| EP4446338A3 (en) | Cells and method of cell culture | |
| UY32732A (es) | Medios para cultivo de células de mamíferos que comprenden sobrenadante del fraccionamiento de cohn y uso de los mismos | |
| EA201170025A1 (ru) | Способы повышения жизнеспособности и продукции культуры клеток | |
| MX2021001981A (es) | Metodos para preparar un poloxamero para usar en medio de cultivo celular. | |
| EA200900984A1 (ru) | Улучшение клеточного роста | |
| MX2021012649A (es) | Medio de cultivo celular para celulas eucarioticas. | |
| GB0720502D0 (en) | Markers of matrix gene expression and cellular differentiation in chondrocytes | |
| TR201106368A2 (tr) | Kıkırdak dokusundan izole edilen kondrosit hücrelerinin üretilmesi için yöntem ve bununla elde edilen kondrosit kültürü. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |